Art. -Nr.: HY-13777A

Zoledronic acid monohydrate

(Synonyms: Zoledronate monohydrate; CGP 42446 monohydrate; CGP42446A monohydrate; ZOL 446 monohydrate)

26 Cited Publications

Kundenbewertung

Based on 26 publication(s) in Google Scholar

Zoledronic acid monohydrate (Zoledronate monohydrate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic acid monohydrate inhibits the differentiation and apoptosis of osteoclasts. Zoledronic acid monohydrate also has anti-cancer effects.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.58%
CAS. Nr.: 165800-06-6
Formel: C₅H₁₂N₂O₈P₂
Molecular Weight:290.10

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Zoledronic acid monohydrate Chemical Structure

CAS. Nr.: 165800-06-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (26)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
BXPC-3	IC₅₀	10 μM Compound: Zoledronate	Cytotoxicity against human BXPC-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human BXPC-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33132173]
Ca-Ski	IC₅₀	10 μM Compound: Zoledronate	Cytotoxicity against human Ca-Ski cells assessed as cell growth inhibition Cytotoxicity against human Ca-Ski cells assessed as cell growth inhibition	[PMID: 33132173]
CFPAC-1	IC₅₀	10 μM Compound: Zoledronate	Cytotoxicity against human CFPAC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human CFPAC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33132173]
Erythrocyte	IC₅₀	>200 μM Compound: NBP3	Antiparasitic activity against Plasmodium falciparum 3D7 infected in human erythrocyte assessed as intraerythrocytic growth inhibition incubated for 24 hrs followed by [3H]hypoxanthine addition by microbeta scintillation counter analysis Antiparasitic activity against Plasmodium falciparum 3D7 infected in human erythrocyte assessed as intraerythrocytic growth inhibition incubated for 24 hrs followed by [3H]hypoxanthine addition by microbeta scintillation counter analysis	[PMID: 33522236]
HCT-116	IC₅₀	61.582 μM Compound: ZOL	Cytotoxicity against FPPS-positive human HCT116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against FPPS-positive human HCT116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31785819]
HeLa	IC₅₀	10 μM Compound: Zoledronate	Cytotoxicity against human HeLa cells assessed as cell growth inhibition Cytotoxicity against human HeLa cells assessed as cell growth inhibition	[PMID: 33132173]
HFF	IC₅₀	0.79 μM Compound: 3	In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells) In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)	[PMID: 15857119]
HFF	IC₅₀	7.8 μM Compound: 3	Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 0.60 uM, experiment 1) Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 0.60 uM, experiment 1)	[PMID: 15857119]
HFF	IC₅₀	7.8 μM Compound: 3	Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 0.79 uM, experiment 3) Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 0.79 uM, experiment 3)	[PMID: 15857119]
HFF	IC₅₀	8.3 μM Compound: 3	Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 1.1 uM, experiment 2) Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 1.1 uM, experiment 2)	[PMID: 15857119]
HL-60	IC₅₀	595.8 μM Compound: Zoledronic acid	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 24928399]
Huh-7	IC₅₀	60 μM Compound: Zoledronate	Cytotoxicity against human HuH7 cells after 144 hrs by MTT assay Cytotoxicity against human HuH7 cells after 144 hrs by MTT assay	[PMID: 24607589]
J774	IC₅₀	7.8 μM Compound: Zoledronate	Cytotoxicity against mouse J774 cells assessed as reduction in cell viability Cytotoxicity against mouse J774 cells assessed as reduction in cell viability	[PMID: 24813742]
JJN-3	EC₅₀	9.4 μM Compound: 1	Antiproliferative activity against human JJN-3 after 72 hrs by MTT assay Antiproliferative activity against human JJN-3 after 72 hrs by MTT assay	[PMID: 22390415]
K562	EC₅₀	>100 μM Compound: Zoledronate	Activation of butyrophilin 3A1 in human K562 cells assessed as interferon-gamma production pretreated for 15 mins followed by HMBPP-treated Vgamma9Vdelta2 T cells addition and measured after 20 hrs by ELISA Activation of butyrophilin 3A1 in human K562 cells assessed as interferon-gamma production pretreated for 15 mins followed by HMBPP-treated Vgamma9Vdelta2 T cells addition and measured after 20 hrs by ELISA	[PMID: 31531198]
K562	EC₅₀	23 μM Compound: Zoledronate	Activation of butyrophilin 3A1 in human K562 cells assessed as interferon-gamma production pretreated for 240 mins followed by HMBPP-treated Vgamma9Vdelta2 T cells addition and measured after 20 hrs by ELISA Activation of butyrophilin 3A1 in human K562 cells assessed as interferon-gamma production pretreated for 240 mins followed by HMBPP-treated Vgamma9Vdelta2 T cells addition and measured after 20 hrs by ELISA	[PMID: 31531198]
K562	EC₅₀	79 μM Compound: Zoledronate	Activation of butyrophilin 3A1 in human K562 cells assessed as interferon-gamma production pretreated for 60 mins followed by HMBPP-treated Vgamma9Vdelta2 T cells addition and measured after 20 hrs by ELISA Activation of butyrophilin 3A1 in human K562 cells assessed as interferon-gamma production pretreated for 60 mins followed by HMBPP-treated Vgamma9Vdelta2 T cells addition and measured after 20 hrs by ELISA	[PMID: 31531198]
KB	ED₅₀	63.7 μM Compound: 67	Dose to inhibit the growth of human KB carcinoma cell line Dose to inhibit the growth of human KB carcinoma cell line	[PMID: 16162013]
LoVo	IC₅₀	34.914 μM Compound: ZOL	Cytotoxicity against FPPS-positive human Lovo cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against FPPS-positive human Lovo cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31785819]
MCF7	IC₅₀	23 μM Compound: Zoledronic acid	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 24928399]
MCF7	IC₅₀	27.7 μM Compound: 2	Antiproliferative activity against human MCF7 cell line by MTT assay Antiproliferative activity against human MCF7 cell line by MTT assay	[PMID: 16970405]
MDA-MB-231	IC₅₀	>100 μM Compound: ZOL	Cytotoxicity against FPPS-negative human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against FPPS-negative human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31785819]
MIA PaCa-2	EC₅₀	13.4 μM Compound: 6	Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay	[PMID: 31725297]
NCI-H460	IC₅₀	11.7 μM Compound: 2	Antiproliferative activity against human NCI-H460 cell line by MTT assay Antiproliferative activity against human NCI-H460 cell line by MTT assay	[PMID: 16970405]
PANC-1	EC₅₀	16.1 μM Compound: 6	Cytotoxicity against human PANC1 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay	[PMID: 31725297]
PANC-1	IC₅₀	10 μM Compound: Zoledronate	Cytotoxicity against human PANC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human PANC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33132173]
RPMI-8226	EC₅₀	11 μM Compound: 1	Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay	[PMID: 23998921]
RPMI-8226	EC₅₀	11 μM Compound: 1; ZOL	Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay	[PMID: 30016091]
SF-268	IC₅₀	14.3 μM Compound: 2	Antiproliferative activity against human SF-268 cell line by MTT assay Antiproliferative activity against human SF-268 cell line by MTT assay	[PMID: 16970405]
SiHa	IC₅₀	10 μM Compound: Zoledronate	Cytotoxicity against human SiHa cells assessed as cell growth inhibition Cytotoxicity against human SiHa cells assessed as cell growth inhibition	[PMID: 33132173]
T-cell	EC₅₀	5.4 μM Compound: 4	Effective concentration against human Gamma delta T cells Effective concentration against human Gamma delta T cells	[PMID: 15828834]
T-cell	IC₅₀	170 μM Compound: 1	Activation of human CD4+ Vgamma2/Vdelta2 T cell clone JN.23 assessed as TNF-alpha release after 16 hrs by sandwich ELISA in presence of antigen presenting cell line, CP.EBV Activation of human CD4+ Vgamma2/Vdelta2 T cell clone JN.23 assessed as TNF-alpha release after 16 hrs by sandwich ELISA in presence of antigen presenting cell line, CP.EBV	[PMID: 23610597]
Vero	IC₅₀	35 μM Compound: NBP3	Antiparasitic activity against Trypanosoma cruzi amastigotes infected in vero cells assessed as parasite growth inhibition incubated for 48 hrs by light microscopy Antiparasitic activity against Trypanosoma cruzi amastigotes infected in vero cells assessed as parasite growth inhibition incubated for 48 hrs by light microscopy	[PMID: 33522236]

In Vitro

Zoledronic Acid monohydrate (0.1-1 μM; 48 hours) increases receptor activator of nuclear factor kB ligand (RANKL) and sclerostin mRNA expressions in osteocyte-like MLO-Y4 cells^[2].
Zoledronic Acid monohydrate increases the expression of osteoclastogenesis supporting factor from MLO-Y4 cells^[2].
Zoledronic Acid monohydrate enhances the RANKL expression via IL-6/ JAK2/STAT3 pathway in MLO-Y4 cells^[2].
Zoledronic Acid monohydrate inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways^[3].
Zoledronic Acid monohydrate (10-100 μM; 1-7 days) markedly reduces the viability of MC3T3-E1 cells^[4].
Zoledronic Acid monohydrate (10-100 μM; 1-7 days) induces apoptosis in MC3T3-E1 cells^[4].
Zoledronic Acid monohydrate (10-100 μM; 4 days) inhibits cell viability due to the induction of apoptosis^[4].
Zoledronic Acid monohydrate exerts inhibitory effects on the differentiation and maturation of MC3T3-E1 cells at concentrations <1 μM^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:

MC3T3-E1 cells
Concentration:

0.02 µM , 0.1 µM, 1 µM, 10 µM, 100 µM
Incubation Time:

1 day, 3 days, 5 days, 7 days
Result:

Reduced cells viability at 10 µM and 100 µM.

Apoptosis Analysis^[4]

Cell Line:

MC3T3-E1 cells
Concentration:

0.02 µM , 0.1 µM, 1 µM, 10 µM, 100 µM
Incubation Time:

1 days, 4 days, 7 days
Result:

Increased the number of early apoptotic cells and late apoptotic or necrotic cells at dose-dependent and time-dependent (high concentrations).

Western Blot Analysis^[4]

Cell Line:

MC3T3-E1 cells
Concentration:

0.02 µM , 0.1 µM, 1 µM, 10 µM, 100 µM
Incubation Time:

4 days
Result:

Down-regulated the protein level of inactive caspase-3 and up-regulated the protein level of active caspase-3 at the concentrations of 10 and 100 µM.

In Vivo

Zoledronic Acid monohydrate (0.05 mg/kg; i.p.; weekly; for 3 weeks) increases bone mineral density and content^[5].
Zoledronic Acid monohydrate (0.5-1 mg/kg; i.p.; weekly; for 3 weeks) inhibits both osteoclast and osteoblasts function and bone remodeling in vivo interfering with bone mechanical properties^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Five-week-old C57BL6 mice^[5]
Dosage:

0.05 mg/kg, 0.5 mg/kg, 1 mg/kg
Administration:

Intraperitoneal injection, weekly, for 3 weeks
Result:

Inhibited both osteoclast and osteoblasts function and bone remodeling at 0.5 mg/kg and 1 mg/kg.

Chemical Information

CAS. Nr. 165800-06-6
Appearance Solid
Molecular Weight 290.10
Formel C₅H₁₂N₂O₈P₂
Color White to off-white
SMILES

OC(P(O)(O)=O)(P(O)(O)=O)CN1C=CN=C1.[H]O[H]
Synonyms

Zoledronate monohydrate; CGP 42446 monohydrate; CGP42446A monohydrate; ZOL 446 monohydrate
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (26)

All Histological Imaging/StainingIn Vivo Efficacy StudyCell Migration/Invasion AssayCell Proliferation/Viability AssayWB

Sort by:

Journal Impact Factor

Natl Sci Rev

Chemical engineering of γδ T cells with cancer cell-targeting antibodies for enhanced tumor immunotherapy. [Abstract]

2025 Jun 27;12(8):nwaf256. PMID: 40842867
Nat Commun

Osteocyte mitochondria regulate angiogenesis of transcortical vessels. [Abstract]

2024 Mar 21;15(1):2529. PMID: 38514612

Zoledronic acid monohydrate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Mar 21;15(1):2529. [Abstract]

Representative TRAP staining images of femur cortical bone and quantification of TRAP positive cell number from PBS or zoledronic acid (100 µg/kg, intraperitoneal injection, once per week for 2 weeks) treated 4-week-old Dmp1^Cre-DTA^ki/wt mice.

Zoledronic acid monohydrate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Mar 21;15(1):2529. [Abstract]

Representative confocal images of femur cortical bone and quantitative result of TCVs from PBS or zoledronic acid (100 µg/kg, intraperitoneal injection, once per week for 2 weeks) treated 4-week-old Dmp1^Cre-DTA^ki/wt mice.
ACS Nano

A Dual-Targeted Metal-Organic Framework Based Nanoplatform for the Treatment of Rheumatoid Arthritis by Restoring the Macrophage Niche. [Abstract]

2023 Jul 25;17(14):13917-13937. PMID: 37429012
Gut Microbes

Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell. [Abstract]

2023 Dec;15(2):2249143. PMID: 37635362
J Nanobiotechnology

Matrix micro/nano-topography drives oncogenic signaling and drug response in a 3D osteosarcoma model. [Abstract]

2026 Mar 6;24(1):345. PMID: 41787498
Immun Ageing

Impaired function of Vγ9Vδ2 T cells in frail elderly. [Abstract]

2026 Jan 16;23(1):7. PMID: 41546035
ACS Appl Mater Interfaces

Biomaterial-Based Lymphangiogenesis-Enhanced Therapeutic Strategy for Robustly-Integrated Medication-Related Osteonecrosis of Jaw Prevention. [Abstract]

2025 Jun 25;17(25):36315-36333. PMID: 40518597
Chem Eng J Adv

2026 Feb 16.
JCI Insight

Aerobic exercise prevents renal osteodystrophy via irisin-activated osteoblasts. [Abstract]

2025 Jan 30;10(5):e184468. PMID: 39883525

Zoledronic acid monohydrate purchased from MedChemExpress. Usage Cited in: JCI Insight. 2025 Jan 30;10(5):e184468. [Abstract]

Serum creatinine, urea nitrogen, and uric acid levels in CKD mice or sham-operated mice (Zoledronic Acid: i.p., 20/100 μg/kg, once per day, 4 weeks).
Eur J Med Chem

Innovative medicinal chemistry strategies for enhancing drug solubility. [Abstract]

2024 Dec 5:279:116842. PMID: 39260319
Life Sci

A three-dimensional dynamic in vitro bone remodeling model reveals multicellular effects of anti-osteoporotic agents. [Abstract]

2026 Jun 15:395:124396. PMID: 41990913
Commun Biol

Mevalonate pathway inhibition reduces bladder cancer metastasis by modulating RhoB protein stability and integrin β1 localization. [Abstract]

2024 Nov 9;7(1):1476. PMID: 39521858

Zoledronic acid monohydrate purchased from MedChemExpress. Usage Cited in: Commun Biol. 2024 Nov 9;7(1):1476. [Abstract]

Representative images and statistical graph of transwell assays from the indicated groups after treatment with ZOL at different concentrations (0, 10 and 20 μM) in UM-UC-3 cells and T24 cells for 48 h.

Zoledronic acid monohydrate purchased from MedChemExpress. Usage Cited in: Commun Biol. 2024 Nov 9;7(1):1476. [Abstract]

An MTT assay was performed to detect changes in the proliferation of BLCA cells (UM-UC-3, T24 and 5637) after treatment with different concentrations (0, 1, 2, 5, 10, 20, 40, 60 and 80 μM) of ZOL for 48 h.

Zoledronic acid monohydrate purchased from MedChemExpress. Usage Cited in: Commun Biol. 2024 Nov 9;7(1):1476. [Abstract]

Western blot analyses of EMT-related proteins in ZOL-treated ((0, 10 and 20 μM, 48 h) UM-UC-3, T24 and 5637 cells. GAPDH was used as the loading control.

Zoledronic acid monohydrate purchased from MedChemExpress. Usage Cited in: Commun Biol. 2024 Nov 9;7(1):1476. [Abstract]

ZOL (100 μg/kg, intraperitoneally injection, three times a week for 4 weeks). Representative images of H&E-stained mouse lung tissue sections (n = 3)and statistical analysis of the number of metastatic nodules in H&E-stained mouse lung tissue sections.
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Int Immunopharmacol

Zoledronic acid enhances the efficacy of immunotherapy in non-small cell lung cancer. [Abstract]

2022 Sep:110:109030. PMID: 35978519
Med Oncol

Zoledronic acid induces ferroptosis by upregulating POR in osteosarcoma. [Abstract]

2023 Apr 10;40(5):141. PMID: 37036615
Bone

Zoledronic acid relieves steroid-induced avascular necrosis of femoral head via inhibiting FOXD3 mediated ANXA2 transcriptional activation. [Abstract]

2024 Nov:188:117222. PMID: 39102974
J Orthop Surg Res

Localized therapeutic strategy based on microRNA-21-loaded mesoporous silica nanoparticles hydrogel improves bone repair in medication-related osteonecrosis of the jaw. [Abstract]

2025 Dec 23;20(1):1079. PMID: 41437101
J Dent Sci

2026 Jan 20.
J Dent Sci

Beta-adrenergic receptor antagonist propranolol prevents bisphosphonate-related osteonecrosis of the jaw by promoting osteogenesis. [Abstract]

2025 Jan;20(1):539-552. PMID: 39873080
Int J Parasitol Drugs Drug Resist

Promising efficacy of nitrogen-containing bisphosphonates against the infection of Cryptosporidium spp. [Abstract]

2025 Aug 6:29:100607. PMID: 40782657
Appl Biochem Biotechnol

Zoledronic Acid Accelerates ER Stress-Mediated Inflammation by Increasing PDE4B Expression in Bisphosphonate-Related Osteonecrosis of the Jaw. [Abstract]

2024 Oct;196(10):7362-7374. PMID: 38523176
bioRxiv

2026 Mar 29.
SSRN

2025 Sep 23.
bioRxiv

2025 March 11.
Dis Markers

Study on the Killing Effect of γδ T Cells Activated by Rukangyin on Breast Cancer MDA-MB-231 Cells. [Abstract]

2021 Oct 15;2021:5838582. PMID: 34691287
Oxid Med Cell Longev

Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis. [Abstract]

2021 Mar 30:2021:6661534. PMID: 33859780

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 28.57 mg/mL (98.48 mM; ultrasonic and adjust pH to 9 with 1 M NaOH)

H₂O : 14.29 mg/mL (49.26 mM; ultrasonic and adjust pH to 8 with NaOH)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4471 mL

17.2354 mL

34.4709 mL

5 mM

0.6894 mL

3.4471 mL

6.8942 mL

10 mM

0.3447 mL

1.7235 mL

3.4471 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 3.33 mg/mL (11.48 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Lianwei Wang, et al. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review. BMC Cancer. 2020; 20: 1059. [Content Brief]

[2]. Hyung Joon Kim, et al. Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis. Int J Mol Sci. 2019 Mar; 20(6): 1467. [Content Brief]

[3]. Xiao-Lin Huang, et al. Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways. Int J Mol Med. 2019 Aug;44(2):582-592. [Content Brief]

[4]. XIN HUANG, et al. Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro. Mol Med Rep. 2016 Jan; 13(1): 613-622. [Content Brief]

[5]. Samantha Pozzi, et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009 Sep 15;15(18):5829-39. [Content Brief]

[6]. Shea GKH, et al. Oral Zoledronic acid bisphosphonate for the treatment of chronic low back pain with associated Modic changes: A pilot randomized controlled trial. J Orthop Res. 2022 Feb 23. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / H₂O	1 mM	3.4471 mL	17.2354 mL	34.4709 mL	86.1772 mL
	5 mM	0.6894 mL	3.4471 mL	6.8942 mL	17.2354 mL
	10 mM	0.3447 mL	1.7235 mL	3.4471 mL	8.6177 mL
	15 mM	0.2298 mL	1.1490 mL	2.2981 mL	5.7451 mL
	20 mM	0.1724 mL	0.8618 mL	1.7235 mL	4.3089 mL
	25 mM	0.1379 mL	0.6894 mL	1.3788 mL	3.4471 mL
	30 mM	0.1149 mL	0.5745 mL	1.1490 mL	2.8726 mL
	40 mM	0.0862 mL	0.4309 mL	0.8618 mL	2.1544 mL
H₂O	50 mM	0.0689 mL	0.3447 mL	0.6894 mL	1.7235 mL
	60 mM	0.0575 mL	0.2873 mL	0.5745 mL	1.4363 mL
	80 mM	0.0431 mL	0.2154 mL	0.4309 mL	1.0772 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Zoledronic acid monohydrate

26 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Zoledronic acid monohydrate

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Zoledronic acid monohydrate

Biologische Aktivität

Chemical Information

Publications (26)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Zoledronic acid monohydrate

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

Publications Citing Use of MedChemExpress (MCE) Zoledronic acid monohydrate

Biologische Aktivität

Chemical Information

Publications (26)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Zoledronic acid monohydrate Related Classifications

HY-13777A Related Classifications